Infant Bacterial Therapeutics AB (publ) (IBT-B) - Net Assets
Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has net assets worth Skr124.36 Million SEK (≈ $13.38 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr178.23 Million ≈ $19.18 Million USD) and total liabilities (Skr53.87 Million ≈ $5.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Infant Bacterial Therapeutics AB (publ) liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr124.36 Million |
| % of Total Assets | 69.77% |
| Annual Growth Rate | 58.84% |
| 5-Year Change | -61.32% |
| 10-Year Change | 127.6% |
| Growth Volatility | 304.58 |
Infant Bacterial Therapeutics AB (publ) - Net Assets Trend (2013–2024)
This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore IBT-B total assets for the complete picture of this company's asset base.
Annual Net Assets for Infant Bacterial Therapeutics AB (publ) (2013–2024)
The table below shows the annual net assets of Infant Bacterial Therapeutics AB (publ) from 2013 to 2024. For live valuation and market cap data, see IBT-B company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr170.26 Million ≈ $18.32 Million |
-44.20% |
| 2023-12-31 | Skr305.15 Million ≈ $32.84 Million |
-8.00% |
| 2022-12-31 | Skr331.71 Million ≈ $35.70 Million |
-16.08% |
| 2021-12-31 | Skr395.25 Million ≈ $42.54 Million |
-10.20% |
| 2020-12-31 | Skr440.15 Million ≈ $47.37 Million |
-13.76% |
| 2019-12-31 | Skr510.40 Million ≈ $54.93 Million |
-8.32% |
| 2018-12-31 | Skr556.72 Million ≈ $59.91 Million |
+230.65% |
| 2017-12-31 | Skr168.37 Million ≈ $18.12 Million |
+60.01% |
| 2016-12-31 | Skr105.23 Million ≈ $11.32 Million |
+40.66% |
| 2015-12-31 | Skr74.81 Million ≈ $8.05 Million |
+578.17% |
| 2014-12-31 | Skr11.03 Million ≈ $1.19 Million |
+952.42% |
| 2013-12-31 | Skr1.05 Million ≈ $112.80K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Infant Bacterial Therapeutics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60224915300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr3.67 Million | 2.16% |
| Other Components | Skr768.84 Million | 451.56% |
| Total Equity | Skr170.26 Million | 100.00% |
Infant Bacterial Therapeutics AB (publ) Competitors by Market Cap
The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United Polyfab Gujarat Limited
NSE:UNITEDPOLY
|
$75.56 Million |
|
Inovio Pharmaceuticals Inc
NASDAQ:INO
|
$75.57 Million |
|
Billion Electric Co Ltd
TW:3027
|
$75.58 Million |
|
QPM Energy Ltd
AU:QPM
|
$75.61 Million |
|
Yusin Holding Corp
TW:4557
|
$75.49 Million |
|
Hotel Holiday Garden
TW:2702
|
$75.49 Million |
|
District Metals Corp
V:DMX
|
$75.49 Million |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
$75.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Infant Bacterial Therapeutics AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 305,154,000 to 170,263,000, a change of -134,891,000 (-44.2%).
- Net loss of 136,905,000 reduced equity.
- Share repurchases of 2,013,000 reduced equity.
- New share issuances of 2,013,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 2,015,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-136.91 Million | -80.41% |
| Share Repurchases | Skr2.01 Million | -1.18% |
| Share Issuances | Skr2.01 Million | +1.18% |
| Other Comprehensive Income | Skr-1.00K | -0.0% |
| Other Changes | Skr2.02 Million | +1.18% |
| Total Change | Skr- | -44.20% |
Book Value vs Market Value Analysis
This analysis compares Infant Bacterial Therapeutics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2281.66x to 4.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.02 | Skr53.90 | x |
| 2013-12-31 | Skr0.51 | Skr53.90 | x |
| 2014-12-31 | Skr5.76 | Skr53.90 | x |
| 2015-12-31 | Skr36.50 | Skr53.90 | x |
| 2016-12-31 | Skr20.81 | Skr53.90 | x |
| 2017-12-31 | Skr30.09 | Skr53.90 | x |
| 2018-12-31 | Skr51.60 | Skr53.90 | x |
| 2019-12-31 | Skr45.46 | Skr53.90 | x |
| 2020-12-31 | Skr39.21 | Skr53.90 | x |
| 2021-12-31 | Skr35.21 | Skr53.90 | x |
| 2022-12-31 | Skr29.55 | Skr53.90 | x |
| 2023-12-31 | Skr24.68 | Skr53.90 | x |
| 2024-12-31 | Skr12.64 | Skr53.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Infant Bacterial Therapeutics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3422625.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.41x
- Recent ROE (-80.41%) is below the historical average (-27.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -3.54% | 0.00% | 0.00x | 1.00x | Skr-6.52K |
| 2014 | -61.16% | 0.00% | 0.00x | 1.32x | Skr-7.85 Million |
| 2015 | -27.57% | 0.00% | 0.00x | 1.10x | Skr-28.10 Million |
| 2016 | -36.21% | -23522.22% | 0.00x | 1.05x | Skr-48.63 Million |
| 2017 | -21.47% | -15191.60% | 0.00x | 1.04x | Skr-52.99 Million |
| 2018 | -7.29% | 0.00% | 0.00x | 1.01x | Skr-96.28 Million |
| 2019 | -9.22% | 0.00% | 0.00x | 1.02x | Skr-98.08 Million |
| 2020 | -16.43% | 0.00% | 0.00x | 1.02x | Skr-116.33 Million |
| 2021 | -11.38% | 0.00% | 0.00x | 1.03x | Skr-84.52 Million |
| 2022 | -19.73% | -545425.00% | 0.00x | 1.05x | Skr-98.62 Million |
| 2023 | -40.33% | -159828.57% | 0.00x | 1.15x | Skr-153.58 Million |
| 2024 | -80.41% | -3422625.00% | 0.00x | 1.41x | Skr-153.93 Million |
Industry Comparison
This section compares Infant Bacterial Therapeutics AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $192,506,524
- Average return on equity (ROE) among peers: -72.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Infant Bacterial Therapeutics AB (publ) (IBT-B) | Skr124.36 Million | -3.54% | 0.43x | $75.51 Million |
| 2cureX AB (2CUREX) | $5.10 Million | -80.96% | 0.52x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $249.47K | -25.14% | 8.67x | $8.97 Million |
| Active Biotech AB (ACTI) | $30.67 Million | -149.35% | 0.44x | $17.19 Million |
| Alzinova AB (ALZ) | $96.02 Million | -6.77% | 0.05x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $23.77 Million | -156.33% | 0.35x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $24.44 Million | -126.54% | 0.26x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $258.50 Million | -81.44% | 0.20x | $14.33 Million |
| BioInvent International AB (BINV) | $394.25 Million | 11.71% | 0.13x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $1.02 Billion | 37.50% | 0.37x | $2.59 Billion |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more